Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis reported the longest median overall survival for any treatment in a global Phase 3 trial in uHCCCombination is the only uHCC therapy to increase median overall survival to approximately two years with greater than one in three patients alive at three years FORT LEE, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the landmark overall survival (OS) analysis of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) will be presented at an in-person poster presentation during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1.

第三阶段CARES-310研究发现，与索拉非尼相比，卡美利珠单抗和利沃西尼联合治疗作为uHCC的一线治疗继续显示出持续的长期生存期。最终分析报告称，在uHCC的全球第三阶段试验中，任何治疗的中位总生存期最长。联合治疗是唯一一种将中位总生存期提高至约两年的uHCC治疗方法，三分之一以上的患者在2024年5月30日的新泽西州李堡（FortLee）（环球通讯社）——HLB Co.，Ltd.的控股子公司Elever Therapeutics，Inc.今天宣布对卡美利珠单抗和利沃西尼进行具有里程碑意义的总生存期（OS）分析6月1日，2024年美国临床肿瘤学会（ASCO）年会期间，不可切除肝细胞癌（uHCC）的线治疗将在面对面的海报展示中介绍。

The abstract can be viewed at asco.org/abstracts. “The CARES-310 final OS analysis confirmed statistically superior and clinically meaningful survival improvement with a manageable safety profile for the combination of camrelizumab and rivoceranib as a first-line treatment for patients suffering from unresectable hepatocellular carcinoma,” said Saeho Chong, Elevar chief executive officer.

摘要可以在asco.org/abstracts上查看。LEVAR首席执行官Saeho Chong说：“CARES-310最终OS分析证实，作为不可切除肝细胞癌患者的一线治疗，卡美利珠单抗和利沃西尼联合使用具有统计学上优越且临床意义的生存改善，具有可控的安全性。”。

“These data confirm that the novel combination therapy represents a clinically differentiated improvement to the standard of care in first-line treatments for uHCC.” “The CARES-310 landmark analysis reported the longest median overall survival for any treatment in a global Phase 3 trial in the uHCC setting,” said Ahmed Omar Kaseb, M.D., professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

“这些数据证实，这种新型联合疗法代表了对uHCC一线治疗标准的临床差异化改进。”“CARES-310里程碑式分析报告说，在uHCC环境下的全球3期试验中，任何治疗的中位总生存期最长，”德克萨斯大学MD安德森癌症中心癌症医学部胃肠医学肿瘤学系教授Ahmed Omar Kaseb说。

“The combination of camrelizumab and rivoceran.

“camrelizumab和rivoceran的组合。